Key Highlights

● Fiscal second-quarter Revenue rose and most segments gained profit

● Full-year outlook was raised

● Shares slipped as attention turned to second-half spending

● Sustainability of growth drew investor questions

McKesson Corporation (NYSE:MCK), one of the bellwether Blue-Chip names in US healthcare services, reported fiscal second-quarter results and lifted its adjusted Earnings guidance for the full year. A company notice carried on the wire said the results were released from its Irving, Texas, headquarters ahead of a webcast that afternoon, and market data published the same day highlighted the guidance increase.

Details from the company's Quarterly Report and from market data, in an article, show that revenue, Operating Income and Diluted Earnings per Share all rose from the prior-year period. According to market data, both adjusted earnings per share and revenue came in above its consensus estimate. Even so, the shares fell modestly in after-hours trading, according to the same report, even though the stock had already gained strongly this year, comfortably ahead of both its industry and the S&P 500.

That reaction gives the report its main tension. The headline numbers were higher nearly everywhere, but the questions that followed centered on how durable the pace of growth may be, how much the company intends to invest in the back half of its fiscal year and how a series of recent transactions will fit together.

What the Filing Shows

McKesson's quarterly report filed with the US Securities and Exchange Commission gives the company-wide framework for the period. Revenue rose from the prior-year quarter, as did operating income and Net Income attributable to the company. Diluted earnings per share climbed at a faster rate than net income because the share count declined.

Over the first half of the fiscal year, the picture was more mixed. Revenue and operating income both rose, but net income attributable to the company actually slipped from the year-earlier period. Diluted earnings per share still edged higher, again because the share count fell. Restructuring charges increased, both in the quarter and over the first half.

On an adjusted basis, According to market data, Gross Profit rose faster than revenue, adjusted operating expenses rose more slowly than gross profit, and adjusted Operating Margin widened slightly. Adjusted earnings per share increased at a high-teens rate, helped by the lower share count. The adjusted operating margin remains a very thin slice of revenue, so even a small shift in that margin translates into a substantial change in profit dollars.

North American Pharmaceutical Sets the Pace

The North American Pharmaceutical segment remains by far the largest of the company's businesses. According to market data, its revenue rose at a mid-single-digit rate and adjusted operating profit climbed by more than a fifth from the prior-year quarter. The revenue comparison was held back by lower branded drug pricing that followed list-price cuts in January, which reduced segment revenue growth by a few percentage points without a meaningful effect on segment profit, a sign that reported revenue and earnings do not always move together in distribution.

Medications in the glucagon-like peptide class remain a large part of the Volume story. Market data and a transcript of the Earnings Call both put distribution revenue from these products up by about a quarter from the year-earlier period. Chief Financial Officer Kenny Cheung noted that Demand is strong, though quarterly results can vary with payer dynamics.

The full-year outlook for this segment now calls for mid-teens profit growth,. Because this is the largest business, that pace carries considerable weight in the group outlook. Market commentary identified the sustainability of such profit growth as a possible source of investor concern.

Oncology and Multispecialty: Growth With a Comparison Wrinkle

The Oncology and Multispecialty segment posted rapid revenue growth. Reported adjusted operating profit growth looked more moderate at a high single-digit rate, but the prior-year figure included gains at The US Oncology Network. Excluding those gains, market data calculated a growth rate of more than a fifth, which is the better reading of underlying momentum.

According to the call transcript, Cheung said same-store patient visits had reached their highest level in recent quarters across the company's networks. The segment's weight within McKesson is also about to increase. The quarterly report says that the Precision Medicine Group and Spectrum Vision acquisitions, both closed in early November, will be reported in Oncology and Multispecialty starting with the fiscal third quarter.

The full-year profit growth outlook for the segment stands in the high teens to low twenties. Readers comparing the results across periods will want to keep in mind the additional effect of these acquisitions, as well as the prior-year gains that affect the current comparison.

A Busy Season for Deals

Precision Medicine Group is the largest of the recently closed transactions, at a price in the billions of dollars. It closed on the before the results and is expected to add a small amount to adjusted earnings per share in the current fiscal year. The transcript indicates that management expects a larger contribution by the third year of ownership.

Spectrum Vision, the other closed deal, gives McKesson a controlling interest in a Business whose purchase price the quarterly report puts in the hundreds of millions of dollars, subject to customary post-closing adjustments. The filing notes that the Fair Value analysis for the transaction is still under way, so its Balance Sheet treatment remains preliminary.

A larger move is still pending. In early October, McKesson and CD&R announced an agreement to acquire Option Care Health (NASDAQ:OPCH), which the announcement described as the nation's largest independent home and alternate site infusion provider. CD&R is to take a majority stake, and McKesson will invest for a minority stake just under half. The arrangement sets up a framework under which McKesson could later acquire CD&R's interest, subject to conditions and regulatory approvals.

McKesson's stated rationale points to growing demand for specialty, rare and orphan therapies and for alternate infusion services. Chair and Chief Executive Officer Brian Tyler said in the announcement, “This Investment represents an important opportunity that aligns with McKesson's long-term strategy.” The deal is expected to close in the first half of next calendar year. McKesson plans to use Equity method accounting for its stake, and the transcript indicates that current guidance excludes any contribution from it.

The announcement gave the company a multibillion-dollar Enterprise value and put the offer at a sizable premium to the prior day's closing price. Option Care Health is to remain a separate company under its own management team, although its shares will leave Nasdaq and it will become private once the deal closes. The transaction requires approval from Option Care Health stockholders and regulators. Chief Executive Officer John C. Rademacher described it in the announcement as a great outcome for the company and its stockholders, while Option Care Health withdrew its guidance for the year and said it would report its third-quarter results without a live conference call.

Distribution relationships also moved. The company extended its Partnership with CVS Health (NYSE:CVS) into the next decade, and a company headline from October said the pharmaceutical distribution agreement had been extended. Cheung said on the call that the extended relationship runs into the next decade, with the new term starting in October, according to the transcript.

Prescription Technology and the Weak Spot in Medical-Surgical

Prescription Technology Solutions, a smaller but high-margin business, recorded double-digit revenue growth and high-teens adjusted operating profit growth. The transcript says the segment added a further group of programs across a range of brands during the quarter, and that its payer network covers the great majority of US prescription volume.

The same transcript includes a note of caution. Cheung said prior authorization volumes tied to a Medicare bridge program for glucagon-like peptide medications “have begun to normalize” after strong initial demand. The quarterly report also shows that restructuring charges tied to this segment were recorded during the period.

Medical-Surgical Solutions is the exception within the portfolio. Revenue rose at a mid-single-digit rate, but adjusted operating profit fell by about a tenth, which Market commentary attributed to an unfavorable ambulatory care mix. Full-year guidance for the segment ranges from a modest decline to flat, a far softer expectation than those for the other segments.

The segment's ownership structure has also changed. The quarterly report states that Apollo (NYSE:APO) Funds acquired a minority interest in Medical-Surgical Solutions in June through a large convertible preferred equity investment, an interest classified as redeemable noncontrolling on the balance sheet. McKesson retains the majority and continues to include the segment in its segment reporting.

Reading the Guidance Change

The headline change was the increase in full-year adjusted earnings per share guidance, with the new range now implying high-teens growth. The range for revenue growth and the range for adjusted operating profit growth also moved higher. Market data also listed the company's expectations for free Cash Flow and share repurchases, both of which remain sizable, for the full year.

By segment, the outlook now shows strong profit growth for North American Pharmaceutical, Oncology and Multispecialty and Prescription Technology Solutions, and softness for Medical-Surgical. The contribution of the closed acquisitions is small in the current fiscal year, based on the figures management gave, so most of the increase appears to come from the existing business.

The transcript also refers to accelerated second-half investment intended to enhance capabilities and support growth, with spending directed at automation, technology and other priorities. Market commentary listed such second-half spending among the possible reasons for the muted share reaction, along with normalizing authorization volumes, Medical-Surgical profit pressure, higher financing costs and possible policy changes. Those reasons are one publisher's interpretation rather than statements from the company.

Cash, Debt and Returns to Shareholders

Operating cash flow for the first half rose sharply from the prior-year period, according to both the quarterly report and market data, and cash and equivalents rose from the end of the fiscal first quarter. Over the same period, McKesson spent heavily on share repurchases, which helps explain why per-share growth has run ahead of net income. The Dividend declared per share also increased from the prior year.

The balance sheet shows the other side of those decisions. Long-term debt rose significantly from the end of the previous fiscal year, reflecting debt issuances during the period, and the stockholders' Deficit widened. Long-term litigation liabilities declined as the company made payments during the half. Market commentary flagged higher financing costs among the issues investors may weigh, and the pending Option Care investment represents a further call on capital.

The filing also records the earlier disposal of the company's operations in Norway, completed in January, which produced a net gain in the prior fiscal year and is part of the reason comparisons need care. It also lists a new restructuring initiative at the corporate level, with charges mainly for severance and exit costs. Those programs are expected to be substantially complete by the end of next fiscal year, while a separate program continues in Prescription Technology Solutions.

Policy Remains a Watch Item

Drug pricing policy is a recurring backdrop for the company. The transcript indicates that a possible move to a rebate model under a federal drug-pricing program in January remains uncertain, and Cheung said management did not anticipate any material financial impact on the business at this time. Tyler noted that McKesson is represented across all channels.

January's list-price reductions on branded medications provide a concrete example of how policy and pricing changes can show up in results. Those reductions cut segment revenue growth without a meaningful effect on profit in this period. Whether future changes prove similarly neutral would depend on their structure, and the company's comments on the possibility of rebate changes were limited to the current assessment.

The Bigger Shape of McKesson

The company describes itself as a diversified healthcare services leader working with biopharma companies, care providers, pharmacies, manufacturers and governments. The quarter illustrated each of those relationships in some way: distribution volumes, oncology networks, prescription technology tied to manufacturers and payers, and policy engagement with federal programs.

It also showed the direction of management's Capital allocation. McKesson is adding specialty and oncology assets, taking an outside partner in Medical-Surgical and committing to home and alternate-site infusion through Option Care. Taken together, those moves tilt the portfolio toward specialty care and complex therapies.

For now, the results give the company a stronger base for the remainder of the fiscal year, even as the after-hours move shows that high expectations are built into the shares. The fiscal third-quarter report, which will be the first to include the newly closed acquisitions in the Oncology and Multispecialty results, will offer the next meaningful test of the raised outlook.